Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Volt Pharma Associates

VPA supports life sciences companies, investors and academic institutes in developing new products, technologies and innovative approaches. VPA’s aim is to solve our clients’ product research, development and commercialisation challenges so they can achieve their business goals.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group logo

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Market access, Regulatory affairs, Research and development

Company Details

Volt Pharma Associates
Engesserstrasse 4B, Freiburg, 79114, Germany
+49 172 6340202
Contact Volt Pharma Associates
Website

 Latest Content from PMHub 

Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens

Press Releases | September 29, 2023 | Medscape Education

From September 27-30, members of the Medscape Education Global team were in Athens, Greece sharing 5 posters at the International Myeloma Society Annual Meeting, 2023.The posters presented the outcomes and...

Top 10 benefits of virtual advisory boards: Save Time and Resources

Videos and Podcasts | September 28, 2023 | Impetus Digital

We've broken down the top ten benefits of why virtual advisory boards are superior to in-person and hybrid advisory boards. #1. Countless Hours of Time-savings and Substantially Reduced Costs We’ll...

Impacting Lives with Rare Disease Education

Press Releases | September 26, 2023 | Medscape Education

Education on rare diseases is crucial. Estimates suggest there are approximately 10,000 rare diseases, with 263–446 million people affected worldwide.Since its launch in September 2022, the Medscape Pathways in Rare...

Looking to start activity on a currently unpromoted pharmaceutical brand?

Videos and Podcasts | September 22, 2023 | CHASE

Looking to start activity on your current unpromoted brands in the UK? CHASE can fully manage the renewal of promotion! Get in touch with Richard Baderin on 0131 553 6644 or...

Considering a portfolio review?

Videos and Podcasts | September 22, 2023 | Wilmington Healthcare

Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...

Want the most from your Pharmaceutical portfolio?

Videos and Podcasts | September 22, 2023 | CHASE

Are you looking to maximise your mature pharmaceutical portfolio? With CHASE we can deliver innovative solutions to help your brands reach their potential! Get in touch with Richard Baderin on 0131...

10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm

Videos and Podcasts | September 21, 2023 | Impetus Digital

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

Church Pharmacy increases productivity

Videos and Podcasts | September 19, 2023 | Kardex

Video of how Church pharmacy moved from a traditional to an automated  set up and increased accuracy to 99%

Havas Lynx launches proprietary data product to drive meaningful change across pharma

Press Releases | September 18, 2023 | Havas Lynx

Leading global healthcare communications agency, Havas Lynx , has launched its proprietary data platform, Point.1, to help pharmaceutical companies to gain a deeper understanding of healthcare professionals (HCPs) to drive...

World Environmental Health Day 2023

Press Releases | September 15, 2023 | Mednet

As a business in the health industry, we're always striving to do what we can to help improve the health and well-being of people worldwide.